Your browser doesn't support javascript.
loading
Mostrar: 20 | 50 | 100
Resultados 1 - 20 de 70
Filtrar
1.
Arch Intern Med ; 139(3): 368-9, 1979 Mar.
Artículo en Inglés | MEDLINE | ID: mdl-311624

RESUMEN

Cellulitis due to Haemophilus influenzae type B in adults has only recently been reported. We report a case in which the patient's antibody levels documented an immunologic response to the organism. The efficacy of a new cephalosporin antibiotic, cefoxitin sodium, in treating this infection also was established. Cefoxitin has activity against ampicillin-resistant H influenzae and would be an alternative in treating H influenzae cellulitis.


Asunto(s)
Celulitis (Flemón)/etiología , Infecciones por Haemophilus/complicaciones , Adulto , Cefoxitina/uso terapéutico , Celulitis (Flemón)/tratamiento farmacológico , Infecciones por Haemophilus/tratamiento farmacológico , Haemophilus influenzae/aislamiento & purificación , Humanos , Masculino
2.
Arch Intern Med ; 139(2): 191-4, 1979 Feb.
Artículo en Inglés | MEDLINE | ID: mdl-219789

RESUMEN

Cerebrospinal fluid lymphocytes from 13 patients with nonsuppurative meningitis were cultured with antigens derived from Mycobacterium tuberculosis, Sporotrichum schenckii, and herpes simplex. When CSF lymphocytes from five patients with infections associated with these organisms were incubated with "correct" antigen there was increased incorporation of thymidine. The levels were higher than those seen when the cells were incubated with different antigens or when CSF lymphocytes from patients with other causes for their meningitis were cultured with these antigens. A compartmentalization of antigen-specific cells was suggested as CSF lymphocytes had greater stimulation than did peripheral blood lymphocytes from the same patient when incubated with the correct antigen. Transformational assays of CSF lymphocytes may provide a valuable diagnostic aid in certain cases of chronic meningitis.


Asunto(s)
Activación de Linfocitos , Meningitis/líquido cefalorraquídeo , Adolescente , Adulto , Antígenos Bacterianos , Femenino , Herpes Simple/líquido cefalorraquídeo , Humanos , Masculino , Meningitis Viral/líquido cefalorraquídeo , Persona de Mediana Edad , Mycobacterium tuberculosis/inmunología , Simplexvirus/inmunología , Sporothrix/inmunología , Esporotricosis/líquido cefalorraquídeo , Tuberculosis Meníngea/líquido cefalorraquídeo
3.
Arch Intern Med ; 137(12): 1686-9, 1977 Dec.
Artículo en Inglés | MEDLINE | ID: mdl-412474

RESUMEN

Candida parapsilosis is rarely isolated from blood cultures. Our hospital surveillance detected an increased rate of isolation of C parapsilosis during a four month period. Fourteen postoperative patients receiving intravenous (IV) hyperalimentation and eight burn patients receiving IV albumin were involved. Hectic fever, the major clinical manifestation, was seen in 61% of cases. Therapy in the postoperative patients consisted merely of discontinuing IV catheters and hyperalimentation, while amphotericin B was needed in five of eight burn patients to control persistent fungemia. Epidemiologic analysis identified a source of the organism in the IV-additive preparation room where C parapsilosis was found contaminating a vacuum system. Organisms apparently refluxed into IV bottles when aliquots were removed to accommodate additives. Of 103 patients who received fluids prepared with the contaminated system, 21% became infected with C parapsilosis. Infection surveillance was instrumental in detection and control of the outbreak. Routine guideline should be established to insure the sterility of IV fluids containing additives.


Asunto(s)
Candidiasis/transmisión , Infección Hospitalaria/transmisión , Brotes de Enfermedades , Nutrición Parenteral Total/efectos adversos , Nutrición Parenteral/efectos adversos , Sepsis/transmisión , Adulto , Anciano , Quemaduras/terapia , Candida/aislamiento & purificación , Candidiasis/microbiología , Infección Hospitalaria/microbiología , Humanos , Michigan , Persona de Mediana Edad , Nutrición Parenteral Total/instrumentación , Cuidados Posoperatorios , Complicaciones Posoperatorias/microbiología , Sepsis/microbiología , Infección de Heridas/microbiología
4.
Arch Intern Med ; 157(15): 1709-18, 1997.
Artículo en Inglés | MEDLINE | ID: mdl-9250232

RESUMEN

BACKGROUND: Pneumonia is the leading cause of death due to infectious diseases in the United States; however, the incidence of most infections causing community-acquired pneumonia in adults is not well defined. METHODS: We evaluated all adults, residing in 2 counties in Ohio, who were hospitalized in 1991 because of community-acquired pneumonia. Information about risk factors, symptoms, and outcome was collected through interview and medical chart review. Serum samples were collected from consenting individuals during the acute and convalescent phases, and specific etiologic diagnoses were assigned based on results of bacteriologic and immunologic tests. RESULTS: The incidence of community-acquired pneumonia requiring hospitalization in the study counties in 1991 was 266.8 per 100,000 population; the overall case-fatality rate was 8.8%. Pneumonia incidence was higher among blacks than whites (337.7/100,000 vs 253.9/ 100,000; P < .001), was higher among males than females (291.4 vs 244.8; P < .001), and increased with age (91.6/100,000 for persons aged < 45 years, 277.2/ 100,000 for persons aged 45-64 years, and 1012.3/ 100,000 for persons aged > or = 65 years; P < .001). Extrapolation from study incidence data showed the projected annual number of cases of community-acquired pneumonia requiring hospitalization in the United States to be 485,000. These data provide previously unavailable estimates of the annual number of cases that are due to Legionella species (8000-18,000), Mycoplasma pneumoniae (18,700-108,000), and Chlamydia pneumoniae (5890-49,700). CONCLUSIONS: These data provide information about the importance of community-acquired pneumonia and the relative and overall impact of specific causes of pneumonia. The study provides a basis for choosing optimal empiric pneumonia therapy, and allows interventions for prevention of pneumonia to be targeted at groups at greatest risk for serious illness and death.


Asunto(s)
Hospitalización , Neumonía/epidemiología , Adulto , Negro o Afroamericano/estadística & datos numéricos , Anciano , Infecciones Comunitarias Adquiridas/epidemiología , Infecciones Comunitarias Adquiridas/microbiología , Femenino , Humanos , Incidencia , Masculino , Persona de Mediana Edad , Ohio/epidemiología , Neumonía/etnología , Neumonía/microbiología , Neumonía/mortalidad , Vigilancia de la Población , Población Blanca/estadística & datos numéricos
5.
Arch Intern Med ; 156(15): 1685-92, 1996.
Artículo en Inglés | MEDLINE | ID: mdl-8694667

RESUMEN

BACKGROUND: Legionnaires disease is a common cause of adult pneumonia. Outbreaks of legionnaires disease have been well described, but little is known about sporadically occurring legionnaires disease, which accounts for most infections. Exposure to contaminated residential water sources is I plausible means of disease acquisition. METHODS: Employing a matched case-control study design in 15 hospitals in 2 Ohio counties, we prospectively enrolled 146 adults diagnosed as having nonepidemic, community-acquired legionnaires disease and compared each with 2 hospital-based control patients, matched for age, sex, and underlying illness category. An interview regarding potential exposures was followed by a home survey that included sampling residential sources for Legionella. Interview and home survey data were analyzed to estimate the risk of acquiring legionnaires disease associated with various exposures. RESULTS: Multivariate analysis showed that a nonmunicipal water supply (odds ratio [OR], 2.26; 95% confidence interval [CI], 1.17-4.37), recent residential plumbing repair (OR, 2.39; 95% CI, 1.10-5.18), and smoking (OR, 3.48; 95% CI, 2.09-5.79) were independent risk factors for legionnaires disease. Univariate analysis suggested that electric (vs gas) water heaters (OR, 1.97; 95% CI, 1.10-3.52), working more than 40 hours weekly (OR, 2.13; 95% CI, 1.12-4.07), and spending nights away from home before illness (OR, 1.68; 95% CI, 1.03-2.74) were additional possible risk factors. Lower chlorine concentrations in potable water and lower water heater temperatures were associated with residential Legionella colonization. CONCLUSIONS: A proportion of sporadic cases of legionnaires disease may be residentially acquired and are associated with domestic potable water and disruptions in residential plumbing systems. Potential strategies to reduce legionnaires disease risk include consistent chlorination of potable water, increasing water heater temperatures, and limiting exposure to aerosols after domestic plumbing repairs.


Asunto(s)
Infecciones Comunitarias Adquiridas/etiología , Vivienda , Enfermedad de los Legionarios/etiología , Adulto , Anciano , Análisis de Varianza , Estudios de Casos y Controles , Infecciones Comunitarias Adquiridas/diagnóstico , Infección Hospitalaria/etiología , Humanos , Legionella pneumophila/aislamiento & purificación , Enfermedad de los Legionarios/diagnóstico , Modelos Logísticos , Análisis por Apareamiento , Persona de Mediana Edad , Factores de Riesgo , Ingeniería Sanitaria , Fumar , Abastecimiento de Agua
6.
Arch Intern Med ; 160(10): 1399-408, 2000 May 22.
Artículo en Inglés | MEDLINE | ID: mdl-10826451

RESUMEN

OBJECTIVE: To provide recommendations for the management of community-acquired pneumonia and the surveillance of drug-resistant Streptococcus pneumoniae (DRSP). METHODS: We addressed the following questions: (1) Should pneumococcal resistance to beta-lactam antimicrobial agents influence pneumonia treatment? (2) What are suitable empirical antimicrobial regimens for outpatient treatment of community-acquired pneumonia in the DRSP era? (3) What are suitable empirical antimicrobial regimens for treatment of hospitalized patients with community-acquired pneumonia in the DRSP era? and (4) How should clinical laboratories report antibiotic susceptibility patterns for S pneumoniae, and what drugs should be included in surveillance if community-acquired pneumonia is the syndrome of interest? Experts in the management of pneumonia and the DRSP Therapeutic Working Group, which includes clinicians, academicians, and public health practitioners, met at the Centers for Disease Control and Prevention in March 1998 to discuss the management of pneumonia in the era of DRSP. Published and unpublished data were summarized from the scientific literature and experience of participants. After group presentations and review of background materials, subgroup chairs prepared draft responses, which were discussed as a group. CONCLUSIONS: When implicated in cases of pneumonia, S pneumoniae should be considered susceptible if penicillin minimum inhibitory concentration (MIC) is no greater than 1 microg/mL, of intermediate susceptibility if MIC is 2 microg/ mL, and resistant if MIC is no less than 4 microg/mL. For outpatient treatment of community-acquired pneumonia, suitable empirical oral antimicrobial agents include a macrolide (eg, erythromycin, clarithromycin, azithromycin), doxycycline (or tetracycline) for children aged 8 years or older, or an oral beta-lactam with good activity against pneumococci (eg, cefuroxime axetil, amoxicillin, or a combination of amoxicillin and clavulanate potassium). Suitable empirical antimicrobial regimens for inpatient pneumonia include an intravenous beta-lactam, such as cefuroxime, ceftriaxone sodium, cefotaxime sodium, or a combination of ampicillin sodium and sulbactam sodium plus a macrolide. New fluoroquinolones with improved activity against S pneumoniae can also be used to treat adults with community-acquired pneumonia. To limit the emergence of fluoroquinolone-resistant strains, the new fluoroquinolones should be limited to adults (1) for whom one of the above regimens has already failed, (2) who are allergic to alternative agents, or (3) who have a documented infection with highly drug-resistant pneumococci (eg, penicillin MIC > or =4 microg/mL). Vancomycin hydrochloride is not routinely indicated for the treatment of community-acquired pneumonia or pneumonia caused by DRSP.


Asunto(s)
Antibacterianos/uso terapéutico , Infecciones Comunitarias Adquiridas/tratamiento farmacológico , Resistencia a Múltiples Medicamentos , Neumonía Neumocócica/tratamiento farmacológico , Streptococcus pneumoniae/efectos de los fármacos , Adulto , Antibacterianos/efectos adversos , Quimioterapia Combinada/efectos adversos , Quimioterapia Combinada/uso terapéutico , Humanos , Lactamas , Pruebas de Sensibilidad Microbiana
7.
J Immunol Methods ; 29(2): 111-5, 1979.
Artículo en Inglés | MEDLINE | ID: mdl-383846

RESUMEN

Prior experience with cultures of cerebrospinal fluid lymphocytes indicated a need to develop methods for culturing small numbers of cells. Peripheral blood lymphocytes (PBL) were obtained from 20 normal volunteers. Standard microcultures using 100 X 10(3) PBL/0.2 ml and cultures with 50, 25 and 12.5 X 10(3) in 0.1 ml or 0.2 ml were established in RPMI 1640 with autologous plasma. These cultures were incubated with PHA (1--30 microgram) for 3, 4 and 5 days, pulsed with [3H]thymidine and harvested. In unstimulated cultures, cpm declined linearly with decreasing cell numbers. Standard cultures (100 X 10(3) PBL/0.2 ml) had maximal PHA stimulation (80,916 +/- 6394) at day 3 with 30 microgram PHA. Other 0.2 ml cultures had lower cpm. By culturing 25 X 10(3) PBL in 0.1 ml for 3 days cpm were 82,874 +/- 6875 with 30 microgram PHA and 77,153 +/- 6022 with 15 microgram PHA and were similar to standard cultures. Similar cpm were seen with 12.5 X 10(3) PBL in 0.1 ml after 4 days with 30 micrograms of PHA (80,838 +/- 6674) and with 15 micrograms of PHA (72,860 +/- 6243), and also after 5 days with 30 micrograms of PHA (86,703 +/- 6732) and with 15 micrograms of PHA (74,066 +/- 6388). The maximal response (126,578 +/- 6580) was seen with 25 X 10(3) PBL/0.1 ml at day 4 with 30 micrograms of PHA. By decreasing culture volume to 0.1 ml and increasing time, the number of cells necessary to give PHA responses similar to standard cultures can be reduced by 75--88%.


Asunto(s)
Técnicas Inmunológicas/métodos , Linfocitos , Células Cultivadas , Humanos , Activación de Linfocitos , Fitohemaglutininas/farmacología
8.
Am J Med ; 87(5A): 164S-168S, 1989 Nov 30.
Artículo en Inglés | MEDLINE | ID: mdl-2589361

RESUMEN

Seventy-one adult patients with 72 infections were treated, by random selection, with intravenous/oral ciprofloxacin or intravenously administered ceftazidime. Twenty-seven additional patients with 29 infections who were not appropriate for random assignment were treated in an open study with intravenously administered ciprofloxacin only; the latter infections were generally more serious or were caused by ceftazidime-resistant organisms. The most common doses were ciprofloxacin, 200 mg intravenously and 500 mg orally every 12 hours and ceftazidime, 1 to 2 g intravenously every eight to 12 hours. Forty-seven ciprofloxacin-treated infections and 31 ceftazidime-treated infections were evaluable for determination of efficacy. Infections included lower respiratory tract (21 infections), urinary (37 infections), skin/soft tissue (14 infections), bacteremia/endocarditis (four infections), colitis (one infection), and mastoiditis (one infection). Median minimal inhibitory concentrations of ciprofloxacin and ceftazidime were, respectively: for Enterobacteriaceae, Haemophilus influenzae, and Branhamella catarrhalis, no more than 0.06 and no more than 0.25 micrograms/ml; for Pseudomonas aeruginosa, 0.25 and 4 micrograms/ml; for Enterococcus faecalis, 1 and more than 32 micrograms/ml; and for Staphylococcus aureus, 0.25 and 8 micrograms/ml. Ciprofloxacin, 200 mg intravenously, yielded mean serum concentrations 0.5 and eight hours post-intravenous infusion of 2.3 and 0.7 micrograms/ml, respectively. Satisfactory clinical responses were achieved in 17 (81 percent) of 21 patients with intravenous/oral ciprofloxacin, 22 (71 percent) of 31 patients with ceftazidime, and 20 (77 percent) of 26 patients with intravenous ciprofloxacin. The most common treatment failures occurred in complicated skin/soft-tissue infections treated with intravenous/oral ciprofloxacin, complicated urinary tract infections treated with ceftazidime, and necrotizing P. aeruginosa pneumonia treated with intravenous ciprofloxacin; the pneumonia patients all had respiratory failure and had been previously unresponsive to treatment with other appropriate drugs. Serious adverse reactions were observed in three patients, seizures with intravenous ciprofloxacin in two patients, and Clostridium difficile diarrhea with ceftazidime in one patient. We conclude that sequential intravenous/oral ciprofloxacin and ceftazidime were comparable in efficacy and safety; the ability to change from intravenous to oral therapy is a major convenience. Intravenous ciprofloxacin was useful for more serious infections, often caused by ceftazidime-resistant organisms.


Asunto(s)
Infecciones Bacterianas/tratamiento farmacológico , Ciprofloxacina/administración & dosificación , Administración Oral , Adolescente , Adulto , Anciano , Anciano de 80 o más Años , Ciprofloxacina/efectos adversos , Ciprofloxacina/uso terapéutico , Farmacorresistencia Microbiana , Femenino , Humanos , Infusiones Intravenosas , Masculino , Persona de Mediana Edad
9.
Am J Med ; 71(5): 815-22, 1981 Nov.
Artículo en Inglés | MEDLINE | ID: mdl-7304654

RESUMEN

Toxigenic Clostridium difficle is the major cause of antibiotic-associated colitis and is susceptible to vancomycin at fecal concentrations achieved with oral therapy. The effect of oral vancomycin was studied in 16 patients with C. difficile-related diarrhea or colitis, 12 of whom had colitis documented by endoscopy, biopsy, and/or barium enema. Four patients had antibiotic-associated diarrhea and possibly antibiotic-associated colitis, because sigmoidoscopy either showed normal results (two patients) or was not performed (two patients). Nineteen episodes of diarrhea were treated with oral vancomycin in two dosage regimens for three to 14 days. Twelve patients received 2 g daily, and four patients initially received 1 g or less per day. Within 48 hours of the start of vancomycin therapy, 14 of 16 patients (87 percent) showed a decrease in temperature, abdominal pain and diarrhea. Diarrhea ceased completely within two days of the start of vancomycin in nine episodes, within three to seven days in six episodes, and within eight to 14 days in the remaining four episodes, and within eight to 14 days in the remaining four episodes. Diarrhea recurred in two of these patients (12 percent) when the drug inciting the initial episode of colitis was given again 42 days or more after vancomycin therapy was stopped; both patients responded again to retreatment with vancomycin. Oral vancomycin is an effective treatment of C. difficile-related colitis and diarrhea.


Asunto(s)
Infecciones por Clostridium/tratamiento farmacológico , Colitis/tratamiento farmacológico , Diarrea/tratamiento farmacológico , Vancomicina/uso terapéutico , Adolescente , Adulto , Anciano , Colitis/etiología , Diarrea/etiología , Femenino , Humanos , Recién Nacido , Masculino , Persona de Mediana Edad , Recurrencia
10.
Infect Dis Clin North Am ; 12(3): 689-99, ix, 1998 Sep.
Artículo en Inglés | MEDLINE | ID: mdl-9779385
11.
Infect Dis Clin North Am ; 12(3): 569-92, vii, 1998 Sep.
Artículo en Inglés | MEDLINE | ID: mdl-9779379

RESUMEN

Infections caused by M. pneumoniae, C. pneumoniae, and Legionella spp. are important causes of community-acquired pneumonia (CAP). In the past decade, considerable new information has come to light concerning these organisms. Despite this, debate continues concerning the syndromic approach to CAP and the scientific merit of lumping these pathogens together. Because the etiologic diagnosis of these pathogens is established only in a minority of cases, the true prevalence tends to be underestimated. In clinical practice, these pathogens are often empirically treated. More rapid and cost-effective diagnostic techniques are needed so that the clinical course of patients with these infections can be better characterized.


Asunto(s)
Infecciones por Chlamydia/microbiología , Chlamydophila pneumoniae , Legionella pneumophila , Enfermedad de los Legionarios/microbiología , Mycoplasma pneumoniae , Neumonía Bacteriana/microbiología , Antibacterianos/uso terapéutico , Antígenos Bacterianos/análisis , Infecciones por Chlamydia/diagnóstico , Infecciones por Chlamydia/epidemiología , Infecciones por Chlamydia/terapia , Humanos , Enfermedad de los Legionarios/diagnóstico , Enfermedad de los Legionarios/epidemiología , Enfermedad de los Legionarios/terapia , Neumonía Bacteriana/diagnóstico , Neumonía Bacteriana/epidemiología , Neumonía Bacteriana/terapia , Neumonía por Mycoplasma/diagnóstico , Neumonía por Mycoplasma/epidemiología , Neumonía por Mycoplasma/microbiología , Neumonía por Mycoplasma/terapia , Prevalencia
12.
Diagn Microbiol Infect Dis ; 25(1): 43-5, 1996 May.
Artículo en Inglés | MEDLINE | ID: mdl-8831044

RESUMEN

Levofloxacin had excellent activity in vitro against bacteremic isolates of Streptococcus pneumoniae with 495 (99.2%) of 499 isolates being susceptible. A total of 38 (97.4%) of 39 isolates with minimal inhibitory concentrations > or = 0.12 micrograms/ml of penicillin were susceptible to levofloxacin. There was excellent correlation between the disk diffusion and broth microdilution methods for determining susceptibility. Resistant isolates belonged to four different serotypes. There was no increase in proportion of isolates of S. pneumoniae resistant between 1991 and 1994.


Asunto(s)
Antiinfecciosos/farmacología , Bacteriemia/tratamiento farmacológico , Levofloxacino , Ofloxacino/farmacología , Infecciones Estreptocócicas/tratamiento farmacológico , Streptococcus pneumoniae/efectos de los fármacos , Pruebas de Sensibilidad Microbiana , Resistencia a las Penicilinas , Penicilinas/farmacología
13.
Diagn Microbiol Infect Dis ; 28(4): 221-3, 1997 Aug.
Artículo en Inglés | MEDLINE | ID: mdl-9327252

RESUMEN

Isolates of Legionella from 98 patients with Legionnaires' disease hospitalized in Columbus, Ohio, USA between 1991 through 1995 were tested for antimicrobial susceptibility to macrolides and quinolones using the Etest. Most (87%) isolates were Legionella pneumophila serogroup 1. All isolates tested remain susceptible to erythromycin, azithromycin, clarithromycin, ciprofloxacin, ofloxacin, and levofloxacin. In vitro susceptibility testing of Legionella to representative macrolides and quinolones should be considered to detect the emergence of resistant isolates.


Asunto(s)
Antibacterianos/farmacología , Antiinfecciosos/farmacología , Legionella/clasificación , Legionella/efectos de los fármacos , 4-Quinolonas , Técnicas Bacteriológicas , Farmacorresistencia Microbiana , Humanos , Legionella/aislamiento & purificación , Enfermedad de los Legionarios/epidemiología , Enfermedad de los Legionarios/microbiología , Macrólidos , Pruebas de Sensibilidad Microbiana , Ohio/epidemiología , Serotipificación , Especificidad de la Especie
14.
Diagn Microbiol Infect Dis ; 38(2): 79-82, 2000 Oct.
Artículo en Inglés | MEDLINE | ID: mdl-11035237

RESUMEN

Large percentages of patients with community acquired pneumonia (CAP) do not have a defined etiology. Between 1992-1993, 99 acute and convalescent sera were collected from patients with CAP of unknown etiology. The sera were tested using an indirect immunofluorescence antibody assay (IFA) against the following antigens: Legionella pneumophila, serogroups 3,5,6 and 7 and L. longbeachae, L. anisa, L. bozemanii and Legionella-Like Amoebal Pathogens (LLAP). A four-fold rise in titer to at least one of the antigens tested, was seen in 14% of patients; 8% to L. bozemanii, 4% to L. anisa, 2% to S. lyticum, 2% to LLAP 10 and 1% each to LLAP 1, 6 and 9. Two patients reacted to several antigens. These results indicate that other species of legionella may be important in the etiology of CAP. L. bozemanii was the organism identified in the majority of these infections. Better diagnostic studies i.e. cultures, serologies and urinary antigen testing, which recognize legionella isolates other than L. pneumophila serogroup 1 need to be developed.


Asunto(s)
Legionella pneumophila , Legionella , Legionelosis/microbiología , Enfermedad de los Legionarios/microbiología , Neumonía Bacteriana/microbiología , Antígenos Bacterianos/análisis , Antígenos Bacterianos/inmunología , Infecciones Comunitarias Adquiridas/sangre , Infecciones Comunitarias Adquiridas/complicaciones , Infecciones Comunitarias Adquiridas/inmunología , Técnica del Anticuerpo Fluorescente Indirecta , Humanos , Legionella/inmunología , Legionella/aislamiento & purificación , Legionella pneumophila/inmunología , Legionella pneumophila/aislamiento & purificación , Legionelosis/sangre , Legionelosis/complicaciones , Legionelosis/inmunología , Enfermedad de los Legionarios/sangre , Enfermedad de los Legionarios/complicaciones , Enfermedad de los Legionarios/inmunología , Neumonía Bacteriana/sangre , Neumonía Bacteriana/complicaciones , Neumonía Bacteriana/inmunología , Estudios Retrospectivos
15.
Diagn Microbiol Infect Dis ; 3(1): 25-31, 1985 Jan.
Artículo en Inglés | MEDLINE | ID: mdl-3881211

RESUMEN

Patients undergoing elective intraabdominal operations received a three-dose prophylactic regimen of either moxalactam (83 patients) or cefazolin (98 patients) in a blinded, randomized fashion. There was a 9% overall infection rate with 6% for those in the cefazolin group (6/98), and 12% for those treated with moxalactam (10/83) (p = 0.26). Infection rates stratified by types of surgery were similar for both regimens. The drugs were well tolerated, with minimal side effects. Patients at highest risk of infection were those with obstruction of upper gastrointestinal tract and those with pancreatitis. We concluded that moxalactam was no more effective than cefazolin in preventing postoperative infections in this study population.


Asunto(s)
Abdomen/cirugía , Infecciones Bacterianas/prevención & control , Cefazolina/uso terapéutico , Moxalactam/uso terapéutico , Premedicación , Adulto , Anciano , Ensayos Clínicos como Asunto , Femenino , Humanos , Masculino , Persona de Mediana Edad , Complicaciones Posoperatorias/prevención & control , Distribución Aleatoria
16.
Diagn Microbiol Infect Dis ; 28(1): 1-3, 1997 May.
Artículo en Inglés | MEDLINE | ID: mdl-9218912

RESUMEN

Twenty-two urine samples positive for Legionella pneumophila serogroup 1 antigen by EQUATE radioimmunoassay (RIA) (Binax, Portland, ME, USA) were stored at various temperatures and the RIA repeated at 1, 7, 30, 90, and 120 days to evaluate stability of the urinary antigens. The mean ratios of patient/negative control remained stable. Although there was a 10% decrease in the mean ratios after 1 month, changes were not significant. However, individual samples with ratios close to 3 may fall to < 3.


Asunto(s)
Antígenos Bacterianos/orina , Legionella pneumophila/inmunología , Humanos , Enfermedad de los Legionarios/inmunología , Enfermedad de los Legionarios/orina , Preservación Biológica , Estudios Prospectivos , Radioinmunoensayo , Temperatura , Factores de Tiempo
17.
J Infect ; 22(1): 41-4, 1991 Jan.
Artículo en Inglés | MEDLINE | ID: mdl-1900521

RESUMEN

Patients with acquired immunodeficiency syndrome (AIDS) are at risk from many endocrine complications. Pentamidine has been recognised for its potential to cause symptomatic, and even life-threatening hypoglycaemia. We report two cases of diabetes mellitus presenting with ketoacidosis 3 to 4 months after pentamidine therapy for Pneumocystis carinii pneumonia (PCP), and review our experience of dysglycaemia in 58 patients with AIDS treated with pentamidine. These cases emphasise the potential for severe pancreatic toxicity in patients with AIDS. Hyperglycaemia during pentamidine therapy may be a marker for patients at increased risk of developing diabetes mellitus.


Asunto(s)
Síndrome de Inmunodeficiencia Adquirida/complicaciones , Cetoacidosis Diabética/inducido químicamente , Pentamidina/efectos adversos , Adulto , Complicaciones de la Diabetes , Cetoacidosis Diabética/complicaciones , Humanos , Hipoglucemia/inducido químicamente , Hipoglucemia/complicaciones , Insulina/uso terapéutico , Masculino , Persona de Mediana Edad , Neumonía por Pneumocystis/tratamiento farmacológico , Factores de Tiempo
18.
Artículo en Inglés | MEDLINE | ID: mdl-8850487

RESUMEN

Candida species are increasingly assuming a pathogenic role in patients throughout the spectrum of in competence. This case history documents a unique presentation of candidiasis with marked similarity to the zygomycoses in patients with diabetic ketoacidosis and explores the pathogenetic basis for both.


Asunto(s)
Candidiasis Bucal/diagnóstico , Cetoacidosis Diabética/diagnóstico , Enfermedades de los Labios/microbiología , Mucormicosis/diagnóstico , Infecciones Oportunistas/diagnóstico , Adulto , Diabetes Mellitus Tipo 1/complicaciones , Diagnóstico Diferencial , Humanos , Enfermedades de los Labios/diagnóstico , Masculino
19.
Lab Anim ; 14(1): 41-2, 1980 Jan.
Artículo en Inglés | MEDLINE | ID: mdl-7359886

RESUMEN

In 35 normal rabbits the cerebrospinal fluid glucose values ranged between 56 and 135 mg/dl, mean and standard deviation 78 +/- 13 mg/dl. Cerebrospinal total protein values ranged from 16 to 66 mg/dl, mean values were similar to those reported for human cerebrospinal fluid. Depression of the cerebrospinal glucose level in the rabbit may parallel the human situation and prove to be a useful marker of purulent inflammation.


Asunto(s)
Proteínas del Líquido Cefalorraquídeo/análisis , Glucosa/líquido cefalorraquídeo , Conejos/líquido cefalorraquídeo , Animales , Femenino , Masculino
20.
Postgrad Med ; 99(1): 95-102, 105-7, 1996 Jan.
Artículo en Inglés | MEDLINE | ID: mdl-8539212

RESUMEN

Characteristic clinical findings of fever, cough, and rhonchi, together with a new infiltrate on chest films and documentation of a pathogen, establish a diagnosis of infectious pneumonia. Several factors have had an impact on the approach to diagnosis of community-acquired pneumonia by the primary care physician. These include the expanding number of possible pathogens as well as their increasing resistance to antimicrobial therapy. Although the clinical presentation may suggest a specific cause, findings often overlap too much for reliable identification of the specific agent on clinical grounds alone. Isolation of the microorganism or determination of the presence of a specific antigen or antibody is necessary. However, even after extensive studies are performed, the pathogen remains unidentified in 30% to 50% of cases. The primary care physician therefore needs to balance reasonable use of diagnostic tests with empirical therapy.


Asunto(s)
Neumonía/diagnóstico , Humanos , Neumonía/etiología
SELECCIÓN DE REFERENCIAS
DETALLE DE LA BÚSQUEDA